Pulmonary Embolism Market Size, Share and Trends 2026 to 2035

Revenue, 2025

USD 2.70 Bn

Forecast Year, 2035

USD 6.04 Bn

CAGR, 2026 - 2035

8.38%

Report Coverage

Global

What is the Pulmonary Embolism Market Size in the 2026?

The global pulmonary embolism market size was calculated at USD2.70 billion in 2025 and is predicted to increase from USD 2.93 billion in 2026 to approximately USD 6.04 billion by 2035, expanding at a CAGR of 8.38% from 2026 to 2035. The market growth is attributed to the increasing prevalence of venous thromboembolism, aging population, advancements in anticoagulant therapies, and rising healthcare expenditure.

Key Takeaways

• North America dominated the global pulmonary embolism market in 2025.
• Asia Pacific is expected to grow at the fastest CAGR in the market during the forecast period.
• By treatment type, the anticoagulants segment held a dominant position in the market in 2025.
• By treatment type, the thrombolytics segment is expected to grow at the fastest CAGR in the market during the forecast period.
• By patient population, the patients with symptomatic pulmonary embolism segment held a dominant position in the market in 2025.
• By patient population, the patients with high-risk pulmonary embolism segment are expected to grow at the fastest CAGR in the market during the forecast period.
• By drug route of administration, the intravenous segment held a dominant position in the market in 2025.
• By drug route of administration, the subcutaneous segment is expected to grow at the fastest CAGR in the market during the forecast period.
• By drug type, the DOACs segment held a dominant position in the pulmonary embolism market in 2025.
• By drug type, the heparins segment is expected to grow at the fastest CAGR in the market during the forecast period.
• By end-use sector, the hospitals segment held a dominant position in the market in 2025.
• By end-use sector, the clinics segment is expected to grow at the fastest CAGR in the market during the forecast period.

Market Overview

Pulmonary embolism is a life-threatening condition caused by the blockage of an artery in the lungs due to blood clot formation, which prevents blood flow. Risk factors include chronic conditions (cancer and cardiovascular diseases) and lifestyle factors (smoking and obesity).

The pulmonary embolism market growth is driven by the rising incidence rate of cardiovascular diseases, rising awareness among the population, rising elderly population, and advancements in diagnostic techniques. The market is focused on the prevention, management, and treatment of pulmonary embolism with the development, production, and commercialization of diagnostic tools and treatments. Rising healthcare expenditure, technological innovations, regulatory approvals, and evolving healthcare infrastructure are shaping the market.

How AI is Reshaping the Pulmonary Embolism Market?

Artificial Intelligence is rapidly reshaping the market by enhancing diagnostic accuracy, risk assessment, and clinical decision-making. AI-powered algorithms enable analysis of CT pulmonary angiograms and other medical images to detect early signs of pulmonary embolism with greater precision and identify high-risk patients to enable better treatment decisions. Advanced digital platforms enhance imaging workflows and automated detection and triage. AI incorporation is reducing mortality rates and improving patient outcomes by reducing diagnostic turnaround times, personalizing treatment planning, and improving workflow efficiency.

Pulmonary Embolism Market Trends

• Therapeutic Advancements and Drug Innovation: Rising adoption of direct oral anticoagulants (DOACs) and emergence of novel anticoagulants offering advantages such as improved safety profile, ease of use, patient adherence, and treatment outcomes.
• Shift Towards Minimally Invasive and Advanced Care: Adoption of catheter-directed thrombolysis, endovascular procedures, and precision-based treatment approaches, improving recovery and clinical effectiveness.
• Advancement in Diagnostic Technologies and Monitoring: Increasing use of AI-assisted image analysis, advanced diagnostics, integration of telemedicine, and remote patient monitoring to enhance recovery and clinical effectiveness.
• Personalized Treatment and Patient-Centric Care: Tailored treatment plans based on patient risk profiles, greater focus on risk stratification, and improved disease awareness to reduce mortality and complications.
• Rising Investment in Research and Disease Burden: Rising prevalence of risk factors such as obesity and sedentary lifestyles is driving demand for treatment, which is leading to strong research and development activity, clinical trials, collaborations, and innovation in therapeutic approaches.

Market Scope

Segment Insights

Treatment Type Insights

How did the Anticoagulants Segment Lead the Pulmonary Embolism Market?

The anticoagulants segment led the market in 2025. They have emerged as a dominant treatment, forming the foundation of both acute treatment and long-term prevention of recurrent clots. The dominance is supported by strong clinical evidence, a well-established efficacy and safety profile, and treatment guidelines. The widespread adoption of anticoagulants is due to their minimal monitoring requirements, lower bleeding risks, and predictable pharmacokinetics with comparable efficacy to traditional therapies like warfarin. Additionally, factors like aging populations and increased prevalence of cardiovascular disease are key drivers behind the growing preference for anticoagulants in managing pulmonary embolism.

The thrombolytics segment is expected to grow with the highest CAGR in the pulmonary embolism market between 2026 and 2035. They are emerging as an alternative since they offer rapid, life-saving clot dissolution in high-risk and acute pulmonary embolism. Advancements in drug formulations and increased clinical awareness have surged the use of thrombolytics. Additionally, increasing emergency care utilization and improved diagnostic speed are also accelerating demand for thrombolytic therapies.

Patient Population Insights

Which Patient Segment Dominated the Pulmonary Embolism Market in 2025?

The patients with symptomatic pulmonary embolism segment dominated the market in 2025, since these patients present with clear clinical symptoms, driving demand for immediate diagnosis and active therapeutic interventions. Key driving factors include greater mortality risk without treatment, improved outcomes with early diagnosis and treatment, and a higher risk of recurrence. To meet the rising management needs of patients with symptomatic pulmonary embolism, make them the largest contributors to the market demand.

The patients with high-risk pulmonary embolism segment are expected to grow at the highest CAGR in the market between 2026 and 2035, since these patients often face significant complications, boosting for immediate and intensive treatment. The segment is fueled by increasing awareness and improved diagnostic methods has increased identification and treatment rates.

Drug Route of Administration Insights

What made the Intravenous Segment Dominate the Pulmonary Embolism Market in 2025?

The intravenous segment dominated the market in 2025. It plays a critical role in the treatment of acute conditions effectively by the rapid onset of action. It is the most preferred route of administration in emergency and hospital settings, particularly for high-risk or unstable patients, since it enables rapid drug delivery, precise dose control, and continuous monitoring. Intravenous therapy is recommended as standard early management, supporting its adoption and market dominance.

The subcutaneous segment is expected to grow with a higher CAGR in the market between 2026 and 2035. The segment is emerging as the fastest-growing alternative due to an increase in outpatient treatments and a growing preference for self-administration among patients, reducing the need for hospital visits. Advances in drug formulations and innovations in biologics are driving the growth of the segment.

Drug Type Insights

Why DOACs Segment Dominated the Pulmonary Embolism Market in 2025?

The DOACs segment dominated the market in 2025, indicating their strong adoption in the treatment of pulmonary embolism by offering effective, safe, and highly convenient long-term anticoagulation. They provide more predictable pharmacokinetics, fixed dosing, minimal food and drug interactions, and less monitoring requirements compared to traditional warfarin treatment. Clinical guidelines have recommended DOACs as the first-line therapy for pulmonary embolism treatment.The market is sustained by rising cardiovascular disease burden and a growing aging population.

The heparins segment is expected to grow at the highest CAGR in the market between 2026 and 2035. It has an essential role in acute and hospital-based management of pulmonary embolism, where rapid anticoagulation is necessary. Their rapid growth can be attributed to their rapid onset, short half-life, and reversibility, enabling clinicians to closely control treatment in unstable patients. Clinical evidence demonstrates reduced clot formation and improved outcomes, supporting its growth in the market.

End-Use Sector Insights

How did the Hospitals Segment Lead the Pulmonary Embolism Market?

The hospitals segment dominated the market in 2025. They serve as the primary point of care and offer well-established infrastructure with advanced diagnostic technologies and access to life-saving therapies. Hospitals provide multidisciplinary teams of healthcare professionals (pulmonologists, radiologists, cardiologists, and emergency medicine specialists) who facilitate the establishment of Pulmonary Embolism Response Teams (PERT Teams), enabling accurate decision-making during emergencies, further strengthening the segment growth.

The clinics segment is expected to grow at the highest CAGR in the market between 2025 and 2035, because there is a shift in the patient care delivery from hospitals to outpatient and community-based settings. These facilities provide more accessible, affordable care and more convenient follow-up care, supporting the expansion of clinics. As healthcare systems focus on cost efficiency, accessibility, and continuity of care, clinics are rapidly expanding in the market.

Regional Insights

What Factors Have Driven the Dominance of North America in the Pulmonary Embolism Market?

North America dominated the global pulmonary embolism market in 2025, due to advanced healthcare infrastructure, high prevalence of risk factors, strong industry presence, and investments in research and development. Key driving factors include widespread availability of diagnostics, growing adoption of AI-powered imaging, access to high-quality treatment solutions, and the increasing incidence of cardiovascular disease. Growing awareness among healthcare professionals and the population, and the presence of key market players, are further driving the market dominance in the region. Strict regulatory requirements, supportive reimbursement policies, and access to advanced diagnostic procedures are leading the region's market share in the market.

U.S. Pulmonary Embolism Market

The U.S. market is expected to evolve at a higher CAGR during the forecast period. The market in the region is driven by advanced healthcare infrastructure, rising awareness, and widespread adoption of advanced diagnostic technologies. The region faces a high risk of cardiovascular disease due to lifestyle factors, obesity, diabetes, and smoking addiction, which continue to increase the incidence of pulmonary embolism. The region has strong support from the U.S. FDA, which enables faster approval and adoption of innovative therapies. The presence of leading pharmaceutical companies in the region accelerates clinical research and enhances treatment availability. The market is further driven by high healthcare spending and expanding outpatient management programs.

What makes Asia Pacific the Fastest Growing Region in the Market?

Asia Pacific is the fastest-growing region in the pulmonary embolism market due to increasing healthcare expenditure, rising awareness of pulmonary diseases, improved access to advanced healthcare systems, and a growing aging population. Countries like China, India, Japan, and South Korea are witnessing a high prevalence of cardiovascular risk factor therefore a higher demand for effective treatment. The region's expanding healthcare infrastructure, growing use of advanced diagnosis technologies, and evolving competitive landscape with companies like Novartis and AstraZeneca are accelerating market growth. Government initiatives, healthcare reforms, and rising medical expenditure are also enhancing treatment accessibility.

Indian Pulmonary Embolism Market

The India market accounted for the largest share in the region, driven by the country's large population, growing healthcare awareness, and increasing access to diagnostics. Enhanced healthcare access in the rural and urban populations, which contributes to earlier detection and management of pulmonary embolism cases, is driven by private and public initiatives. One of the key factors involved in the growth of the market is the government's investments in hospital infrastructure, expanding cardiac care units, and strong regional pharmaceutical manufacturing.

Pulmonary Embolism Market Companies

• Abbott
• Aspen Holdings
• AstraZeneca
• Baxter
• Bayer AG
• Boehringer Ingelheim International GmbH
• Bristol Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Fresenius Kabi AG
• Genentech Inc.
• GlaxoSmithKline plc
• Hikma Pharmaceuticals PLC
• Johnson & Johnson Private Limited
• Merck & Co., Inc.
• Mylan N.V.
• Pfizer Inc.
• Sanofi
• Teva Pharmaceutical Industries Ltd.

Segments Covered in the Report

By Treatment Type

• Anticoagulants
• Thrombolytics
• Mechanical Thrombectomy

By Patient Population

• Patients with Symptomatic Pulmonary Embolism
• Patients with Asymptomatic Pulmonary Embolism
• Patients with High-Risk Pulmonary Embolism

By Drug Route Administration

• Intravenous
• Subcutaneous
• Oral

By Drug Type

• Direct Oral Anticoagulants (DOACs)
• Heparins
• Vitamin K Antagonists

By End-Use Sector

• Hospitals
• Clinics
• Ambulatory Surgical Centers

By Region

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East & Africa